S
Splisense
Developing transformative RNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses
About Splisense
SpliSense is a clinical-stage biotechnology company focused on developing transformative RNA-based treatments for unmet needs in diverse pulmonary diseases. Utilizing clinically validated Antisense Oligonucleotide (ASO) technology, SpliSense delivers its treatments non-invasively by inhalation directly to the lungs. The company is engaged in various stages of drug development, from discovery to Investigational New Drug (IND) applications. SpliSense primarily serves patients suffering from severe pulmonary conditions such as Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF). The company's business model revolves around the research, development, and commercialization of its innovative therapies. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Jerusalem, Israel
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 42.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $13M | — | Cystic Fibrosis Foundation | ↗ |
| SERIES B✓Equity / VC | May 2021 | $29M | $114M | Biotel Limited · OrbiMed · Israel Biotech Fund · Cystic Fibrosis Foundation | — |
Growth signals
Latest recorded traffic for Splisense is 2.6K monthly website visits, up 23.8% over the last three months. Splisense's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Integra Holdings
Series A4 investors entered at this stage
Cystic Fibrosis Foundation- BLBiotel Limited
OrbiMed
Israel Biotech Fund
Other known investors2 additional known investors
The Hebrew University of Jerusalem
Yissum Research Development
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Splisense on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Splisense’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.